Status:
COMPLETED
Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to test if Insulin Detemir as add-on to current Oral Antidiabetic Drug treatment is at least as effect...
Eligibility Criteria
Inclusion
- Type 2 Diabetes for more than 12 months, and no previous insulin treatment
- Oral Antidiabetic Drug treatment for at least 4 months
- Body Mass Index (BMI) less than 40 kg/m2
- HbA1c 7.5-10.0%
Exclusion
- Current or previous treatment with thiazolidinediones within the last 6 months
- Oral Antidiabetic Drug treatment with combination of three or more Oral Antidiabetic Drugs within the last 6 months
- Proliferative retinopathy or maculopathy
- Known hypoglycaemia unawareness
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2004
Estimated Enrollment :
583 Patients enrolled
Trial Details
Trial ID
NCT00283751
Start Date
March 1 2003
End Date
November 1 2004
Last Update
January 27 2017
Active Locations (96)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Greenbrae, California, United States, 94904
2
Novo Nordisk Investigational Site
La Mesa, California, United States, 91942
3
Novo Nordisk Investigational Site
West Palm Beach, Florida, United States, 33401
4
Novo Nordisk Investigational Site
Atlanta, Georgia, United States, 30318